The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Unique mutational landscape and therapeutic implications in non-small cell lung cancer with comorbid fibrotic interstitial lung disease.
 
Jacob Michalski
No Relationships to Disclose
 
Joel Neal
Honoraria - Biomedical Learning Institute; Clinical Care Options; CME Matters; HMP Education; Medical Educator Consortium; Medscape; MJH Life Sciences; Peerview; Prime Oncology; Projects in Knowledge; Research to Practice; Rockpointe CME
Consulting or Advisory Role - Abbvie; Amgen; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; D2G Oncology; Daiichi Sankyo/Astra Zeneca; Exelixis; Genentech/Roche; Gilead Sciences; Iovance Biotherapeutics; Janssen Oncology; Lilly; Mirati Therapeutics; Natera; Novartis; Novocure; Nuvation Bio; Regeneron; Sanofi/Regeneron; Summit Therapeutics; Surface Oncology; Takeda; Turning Point Therapeutics
Research Funding - AbbVie (Inst); Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties